Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.35 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.35 |
| ▸ | CYP3A43 | Q9HB55 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.35 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2801336 | 0.98 | MEN1 (0.41) | MEN1ALDH1A1MAPTPKMALOX15 | |
| Hydrochloric Acid SCHEMBL10317398 | 0.98 | MEN1 (0.41) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL14704914 | 0.93 | MEN1 (0.38) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL16975378 | 0.88 | HCAR2 (0.36) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL28666857 | 0.88 | HCAR2 (0.36) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL16364698 | 0.88 | HCAR2 (0.36) | MEN1ALDH1A1MAPTPKMALOX15 | |
| Hydrochloric Acid SCHEMBL18426762 | 0.86 | HCAR2 (0.35) | MEN1ALDH1A1MAPTPKMALOX15 | |
| Hydrochloric Acid SCHEMBL21840086 | 0.86 | HCAR2 (0.35) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL57030 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL28314935 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288595-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORP (US) | 2025-09-18 | — | — | US | claimed |
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-01 | — | — | US | claimed |
| WO-2020210428-A1 | NOVEL INHIBITORS OF FLAVIVIRUS PROTEASE FOR PREVENTION AND TREATMENT OF ZIKA, DENGUE AND OTHER FLAVIVIRUS INFECTIONS | BAYLOR COLLEGE OF MEDICINE (US) | 2020-10-15 | — | — | WO | claimed |
| CN-111171021-A | Tropomyosin-related kinase (TRK) inhibitors | 建新公司 | 2020-05-19 | — | — | CN | claimed |
| US-10166239-B2 | Tropomyosin-related kinase (Trk) inhibitors | GENZYME CORPORATION (US) | 2019-01-01 | — | — | US | claimed |
| US-20170224704-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2017-08-10 | — | — | US | claimed |
| CN-106232597-A | Tropomyosin-related kinase (TRK) inhibitors | 建新公司 | 2016-12-14 | — | — | CN | claimed |
| EP-3080108-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2016-10-19 | — | — | EP | claimed |
| US-20150274725-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2015-10-01 | — | — | US | claimed |
| US-20150191466-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2015-07-09 | — | — | US | claimed |
| WO-2015089139-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION (US) | 2015-06-18 | — | — | WO | claimed |
| EP-4747250-A1 | KINASE INHIBITORS | The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CYTODYN INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4413985-B1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-05-06 | — | — | EP | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| WO-2004041777-A2 | HETEROARYLPIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-1171122-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1171122-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6248755-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-06-19 | — | — | US | disclosed |
| WO-2000059502-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | MLKL, PCSK9, CTSA | MEN1 751/4885ALDH1A1 3601/4885MAPT 1375/4885 |
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CCR5, CCL2, CCR2 | MEN1 3769/4885ALDH1A1 3326/4885MAPT 2940/4885 |
| US-20150191466-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | MEN1 2734/4885ALDH1A1 3805/4885MAPT 497/4885 |
| US-10166239-B2 | Tropomyosin-related kinase (Trk) inhibitors | NTRK1, NGF, NTRK2 | MEN1 2734/4885ALDH1A1 3805/4885MAPT 497/4885 |
| US-20150274725-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | MEN1 2734/4885ALDH1A1 3805/4885MAPT 497/4885 |
| US-20250288595-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | MEN1 2734/4885ALDH1A1 3805/4885MAPT 497/4885 |
| US-20170224704-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | MEN1 2734/4885ALDH1A1 3805/4885MAPT 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.